Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Teva
Harvard Business School
Queensland Health
Chinese Patent Office
Moodys
McKesson
UBS
Chubb
Fish and Richardson

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,528,530

« Back to Dashboard

Summary for Patent: 6,528,530
Title: Phenidate drug formulations having diminished abuse potential
Abstract:Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Inventor(s): Zeitlin; Andrew L. (Millington, NJ), Dariani; Maghsoud M. (Fanwood, NJ)
Assignee: Celgene Corporation (Warren, NJ)
Application Number:09/955,556
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 6,528,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,528,530

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 306266 ➤ Subscribe
Austria 368458 ➤ Subscribe
Australia 2002318302 ➤ Subscribe
Australia 738521 ➤ Subscribe
Australia 738744 ➤ Subscribe
Australia 7834398 ➤ Subscribe
Australia 7976598 ➤ Subscribe
Canada 2240329 ➤ Subscribe
Canada 2241611 ➤ Subscribe
Canada 2453510 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Covington
Chinese Patent Office
Deloitte
Chubb
Johnson and Johnson
Queensland Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot